Oncolytics更新GOBLET研究时间线：Cohort 4终值数据2026Q4公布、PanCAN尾款2026Q4到账，无新增疗效数据

Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company developing pelareorep, announced an update on its Phase 1/2 GOBLET study, including the expected timing of clinical data releases and receipt of the final payment under its grant from the Pancreatic Cancer Action Network (PanCAN).
Oncolytics expects to receive the final PanCAN grant payment later in the fourth quarter of 2026 following completion of certain activities in Cohort 5.
Patient enrollment in the cohort was completed earlier this year, marking the completion of a key phase of the study, although treatment and follow-up remain ongoing for some participants.
The GOBLET study is evaluating pelareorep-based combination therapies across multiple gastrointestinal cancers.
Cohort 4 is assessing pelareorep in combination with atezolizumab in patients with advanced or unresectable squamous cell anal carcinoma who have received prior treatment.
Cohort 5 is evaluating pelareorep-based therapy with chemotherapy, with or without atezolizumab, in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).
Oncolytics expects to report final results from Cohort 4 in the fourth quarter of 2026. Initial results from Cohort 5 are expected in the first half of 2027, although the timeline could extend as patients continue treatment and follow-up.
The company said median overall survival in Cohort 4 has exceeded its expectations, while the Cohort 5 efficacy data, including overall survival and duration of response, continue to mature. The full data sets are being processed, and additional updates are expected as the analyses progress.
Oncolytics said each cohort that enrolled the required number of patients met its prespecified efficacy success criteria. The company is winding down the broader GOBLET study infrastructure while continuing to monitor remaining patients and prepare for upcoming clinical data readouts.
The GOBLET study has generated clinical and translational data to guide the company's development strategy for pelareorep in combination with checkpoint inhibitors across gastrointestinal and other tumor types. The study is being conducted at 17 centers in Germany under the management of AIO-Studien-gGmbH.
Pelareorep is an investigational intravenous immunotherapy designed to replicate selectively in tumor cells and activate innate and adaptive immune responses against cancer. Oncolytics is developing the therapy in combination with chemotherapy and checkpoint inhibitors for metastatic gastrointestinal cancers, including pancreatic, anal and colorectal cancer.
Currently, ONCY is trading at $0.55, up 13.72%
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.